Literature DB >> 21603363

New horizons in melanoma treatment: targeting molecular pathways.

Christopher W M Soon, Alain P Algazi, Edward N Cha, Adil I Daud.   

Abstract

Entities:  

Keywords:  BRAF V600E; BRAF inhibitors; KIT inhibitors; MEK inhibitors; c-MET inhibitors; kinases; melanoma

Year:  2010        PMID： 21603363      PMCID： PMC3096197     

Source DB:  PubMed          Journal:  Ochsner J        ISSN： 1524-5012


× No keyword cloud information.
  61 in total

1.  Benign nodal nevi frequently harbor the activating V600E BRAF mutation.

Authors:  Janis M Taube; Shanaz Begum; Chanjuan Shi; James R Eshleman; William H Westra
Journal:  Am J Surg Pathol       Date:  2009-04       Impact factor: 6.394

Review 2.  State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer.

Authors:  Marie-France Demierre; Michael S Sabel; Kim A Margolin; Adil I Daud; Vernon K Sondak
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

3.  Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.

Authors:  Jose Lutzky; Juergen Bauer; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2008-05-29       Impact factor: 4.693

4.  Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.

Authors:  H Tsao; X Zhang; K Fowlkes; F G Haluska
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

5.  Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications.

Authors:  Mario A Economou; Charlotta All-Ericsson; Vladimir Bykov; Leonard Girnita; Armando Bartolazzi; Olle Larsson; Stefan Seregard
Journal:  Acta Ophthalmol       Date:  2008-11       Impact factor: 3.761

6.  Oncogenic Braf induces melanocyte senescence and melanoma in mice.

Authors:  Nathalie Dhomen; Jorge S Reis-Filho; Silvy da Rocha Dias; Robert Hayward; Kay Savage; Veronique Delmas; Lionel Larue; Catrin Pritchard; Richard Marais
Journal:  Cancer Cell       Date:  2009-04-07       Impact factor: 31.743

7.  Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.

Authors:  Catherine D Van Raamsdonk; Vladimir Bezrookove; Gary Green; Jürgen Bauer; Lona Gaugler; Joan M O'Brien; Elizabeth M Simpson; Gregory S Barsh; Boris C Bastian
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

8.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330

9.  Phase II trial of imatinib mesylate in patients with metastatic melanoma.

Authors:  K B Kim; O Eton; D W Davis; M L Frazier; D J McConkey; A H Diwan; N E Papadopoulos; A Y Bedikian; L H Camacho; M I Ross; J N Cormier; J E Gershenwald; J E Lee; P F Mansfield; L A Billings; C S Ng; C Charnsangavej; M Bar-Eli; M M Johnson; A J Murgo; V G Prieto
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

10.  A novel AKT3 mutation in melanoma tumours and cell lines.

Authors:  M A Davies; K Stemke-Hale; C Tellez; T L Calderone; W Deng; V G Prieto; A J F Lazar; J E Gershenwald; G B Mills
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640
View more
  1 in total

1.  Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.

Authors:  Qiu Rao; Yan Wang; Qiu-Yuan Xia; Shan-Shan Shi; Qin Shen; Pin Tu; Qun-Li Shi; Xiao-Jun Zhou; Bo Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.